Drug intelligence / Profile preview

DJK-5

Development stage
Preclinical
Lead developer
University of British Columbia
Modality
Small Molecules, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Peptides, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Topical, Inhalation
01

Overview

DJK-5 is a synthetic, all D-enantiomeric (D-amino acid), protease-resistant peptide with broad-spectrum anti-biofilm and antimicrobial activity. It consists of 12 D-amino acids (sequence: H-DVal-DGln-DTrp-DArg-DAla-DIle-DArg-DVal-DArg-DVal-DIle-DArg-NH2; one-letter code: vqwrairvrvir-NH2) and has a molecular weight of approximately 1550.9 Da. Designed to resist enzymatic degradation, DJK-5 disrupts and eradicates established biofilms formed by various bacterial species—including Staphylococcus aureus, Pseudomonas aeruginosa, Streptococcus mutans, Enterococcus faecalis, and Cutibacterium acnes—at concentrations below its minimum inhibitory concentration (MIC). It acts by targeting bacterial membrane integrity and interfering with the stringent stress response in bacteria. In preclinical studies (in vitro and animal models), DJK-5 has demonstrated potent killing of biofilm-associated bacteria as well as synergistic effects when combined with antibiotics such as colistin or daptomycin against multidrug-resistant pathogens in co-biofilms. Its primary research applications are in the prevention and treatment of chronic infections associated with biofilms on medical devices or tissues[1][3][4][7].

Other names
DJK-5 peptideDJK5 peptideDJK 5 peptidevqwrairvrvir-NH2vqwrairvrvir-NH-2vqwrairvrvir-NH 2
02

Targets

ppGpp (Guanosine pentaphosphate)

Beyond the preview

Go deeper on DJK-5.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DJK-5.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call